Amyris Moving 30 Molecules Through R&D Pipeline, Streamlining Consumer Portfolio

Amyris, Inc. is developing 30 molecules using its bio-fermentation technology, negotiating a bio-manufacturing joint venture that could yield $50m-$100m in proceeds, and simplifying its Consumer portfolio to unlock value. Cost containment and liquidity will continue to be key priorities for the synthetic biotech firm while it targets up to 100% revenue growth in fiscal 2023.